
Opinion|Videos|August 12, 2024
Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What gaps remain in identifying likely non-responders to immunotherapy to guide alternative treatments?
- How does the toxicity profile of immuno-oncology regimens compare to standard chemotherapy options?
- Are there ongoing trials or research on novel combination approaches to overcome resistance and improve immunotherapy efficacy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
2
Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies
3
Medicaid Work Requirements Set to Leave Millions Without Insurance
4
FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder
5














































